Results 31 to 40 of about 20,950 (257)

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review

Drugs - Real World Outcomes, 2019
Objectives To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.
Reeti Joshi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Yujin Park, Prashanth Sunkureddi   +5 more
doaj   +1 more source

Secukinumab: a new treatment option for psoriatic arthritis [PDF]

, 2016
Introduction: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life.
McInnes, Iain B., Mease, Philip
core   +1 more source

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Clinical, Cosmetic and Investigational Dermatology, 2023
To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition.
F. Martora, M. Megna, T. Battista, L. Potestio, M. C. Annunziata, C. Marasca, A. Villani, G. Fabbrocini   +7 more
semanticscholar   +1 more source

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5

Chinese Medical Journal, 2020
. Background. Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies.
Feng Huang, Fei Sun, Wei-Guo Wan, Li-Jun Wu, Ling-Li Dong, Xiao Zhang, Tae-Hwan Kim, Raj Sengupta, Ladislav Šenolt, Yi Wang, Hao-Min Qiu, Brian Porter, Sibylle Haemmerle, Li-Shao Guo   +13 more
doaj   +1 more source

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Acta Dermato-Venereologica, 2022
Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
A. Gottlieb, A. Deodhar, I. McInnes, X. Baraliakos, K. Reich, S. Schreiber, W. Bao, K. Marfo, H. Richards, L. Pricop, A. Shete, V. Trivedi, Deborah Keefe, C. Papavassilis, P. Jagiello, P. Papanastasiou, P. Mease, M. Lebwohl   +17 more
semanticscholar   +1 more source

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

Pharmaceuticals, 2022
Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use ...
Vishnu Eshwar, Ashwin Kamath, Rajeshwari Shastry, Ashok K. Shenoy, Priyanka Kamath   +4 more
doaj   +1 more source

Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study

Dermatologic Therapy, 2023
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Biologic drugs have a key role in the long-term anti-inflammatory treatment of moderate to severe patients due to their immunomodulatory properties.
P. Fernández-Crehuet, S. Haselgruber, A. Padial-Gómez, Fiorella Vasquez-Chinchay, M. D. Fernández-Ballesteros, I. López-Riquelme, D. Jiménez‐Gallo, J. M. Segura-Palacios, M. Contreras‐Steyls, Giovana Fernanda Osorio-Gómez, J. Hernández-Rodríguez, M. Sánchez-Díaz, C. Cuenca-Barrales, S. Arias-Santiago, A. Molina‐Leyva   +14 more
semanticscholar   +1 more source

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

Arthritis Research & Therapy, 2018
Background Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among ...
Iain B. McInnes, Philip J. Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M. Jugl, Kunal K. Gandhi, on behalf of the FUTURE 2 Study Group   +10 more
doaj   +1 more source

Comparative Efficacy of Secukinumab Versus Tumor Necrosis Factor Inhibitors for the Treatment of Takayasu Arteritis

Arthritis & Rheumatology, 2023
Tumor necrosis factor (TNF) alpha and interleukin‐17 (IL‐17) are thought to be involved in the pathogenesis of Takayasu arteritis (TAK), and TNF inhibitors (TNFi) are recommended for the treatment of TAK.
X. Tian, Mengtao Li, N. Jiang, Yang Zhao, Jing Li, Yangzhong Zhou, Ya-hong Wang, Ying Wang, Taotao Li, Yun-jiao Yang, Yanhong Wang, P. Merkel, Xiaofeng Zeng   +12 more
semanticscholar   +1 more source

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab

Dermatologica Sinica, 2019
Background/Objective: Secukinumab is an effective treatment for psoriasis, and it has been reported to be effective in patients who failed on multiple prior biologics.
Tai-Siang Chiu, Tsen-Fang Tsai
doaj   +1 more source